Although their numbers were lower than that observed in BS (16.0%) and FMF (17.4%), some exacerbations such as ischemic cardiovascular events in patients with large vessel vasculitis and a new onset IgA vasculitis in a patient with AS who was treated with secukinumab were considerably significant.
← all excerpts
Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine.
1
—
—